Latest News

 

Displaying 1 through 10 of 47  Next Page >>

EndoGastric Solutions Completes $30 Million Financing Round
August 30, 2010
Redwood City, CA (August 30, 2010) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that Canaan Partners and Radius Ventures co-led a $30 Million Series F financing designed to support the company through profitability. Existing investors Advanced Technology Ventures, MPM Capital, Foundation Medical
 
EndoGastric Solutions Announces the Appointment of Floyd Loop, M.D., to Its Board of Directors
August 25, 2010
Redwood City, CA (August 25, 2010) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that Floyd D. Loop, M.D., has joined its Board of Directors. “Dr. Loop is the ideal individual to join our Board of Directors at this stage in the company’s evolution,” said Thierry Thaure, President and Chief Executive Officer
 
EndoGastric Solutions Announces Appointment of Vice President of U.S. Sales
June 21, 2010
Redwood City, CA (June 21, 2010) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), announced today that Mr. Christopher Marrus has joined the company as Vice President of U.S. Sales to continue the company’s rapid commercial growth and expansion. 
 
EndoGastric Solutions Announces Launch of TIF Registry
May 10, 2010
Redwood City, CA (April 28, 2010) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced the launch of the TIF (Transoral Incisionless Fundoplication) Registry Study.
 
First U.S. TIF2 Clinical Outcomes Data Presented at SAGES
April 28, 2010
Redwood City, CA (April 28, 2010) — EndoGastric Solutions (EGS) today announced that new U.S. clinical results for their third generation Transoral Incisionless Fundoplication (TIF2) procedure were presented during the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting April 14-17, in Washington, DC. Clinical outcomes data for over 100 patients
 
3,500th Natural Orifice Surgery Procedure Performed at Advanced CME Course on TIF
February 17, 2010
Redwood City, CA (February 17, 2010) — EndoGastric Solutions (EGS), the leader in the emerging field of Natural Orifice Surgery (NOS), today reported that the 3,500th Natural Orifice Surgery (NOS) procedure was performed in front of the over 110 surgeons from seven countries attending the first Advanced Techniques in Transoral Fundoplication CME course, held
 
EGS Reports Extension of Clinical Evidence Supporting TIF
January 8, 2010
Redwood City, CA (January 8, 2010) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that data from two single-center series demonstrate improved clinical outcomes from a third-generation technique for its Transoral Incisionless Fundoplication (TIF) procedure. This data includes two case series
 
EGS Announces Key Patent Issued
December 31 , 2009
Redwood City, CA (December 31, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that the U.S. Patent and Trademark Office has issued a key patent covering its SerosaFuse fastener and “over the wire” delivery system. Patent no. 7,632,287, entitled "Tissue fixation devices and assemblies
 
EGS Announces Advanced Transoral Fundoplication Educational Course Initiative for 2010
December 9 , 2009
Redwood City, CA (December 9, 2009) — EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced the Advanced Techniques in Transoral Fundoplication CME course series for 2010. The first course, scheduled for January 28-29, 2010, in Denver, CO, will be directed by esteemed surgeons Reginald Bell, MD
 
EGS Announces Additional Financial Investment
November 25, 2009
Redwood City, CA (November 25, 2009) — EndoGastric Solutions (EGS) today announced the closing of a $21.5 Million Series E financing. The funding will be used to support an expanding commercial presence for the company’s market-leading Natural Orifice Surgery (NOS) platform, which includes the EsophyX and StomaphyX surgical devices.

 

Next Page >>

 

Request Info button

 

NP01937-01A